Charles Rudin
Affiliations: | University of Chicago, Chicago, IL |
Area:
Molecular BiologyGoogle:
"Charles Rudin"Parents
Sign in to add mentor| Ursula Storb | grad student | 1986-1991 | Chicago |
| Craig B. Thompson | post-doc | (Chemistry Tree) |
Children
Sign in to add trainee| Robyn S. Karnauskas | grad student | 2004 | Chicago |
| David J. VanderWeele | grad student | 2005 | Chicago |
| Jennifer L. Brace | grad student | 2006 | Chicago |
| Christy R. Hagan | grad student | 2006 | Chicago |
| John Thomas Poirier | grad student | 2006-2012 | Johns Hopkins Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Taniguchi H, Chakraborty S, Takahashi N, et al. (2024) ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science Advances. 10: eado4618 |
| Murciano-Goroff YR, Hui AB, Araujo Filho JA, et al. (2024) Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. Jco Precision Oncology. 8: e2400216 |
| Redin E, Sridhar H, Zhan YA, et al. (2024) SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. Journal of Hematology & Oncology. 17: 58 |
| Elkrief A, Montesion M, Sivakumar S, et al. (2024) Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301488 |
| He T, Xiao L, Qiao Y, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer Cell |
| Tendler S, Dunphy MP, Agee M, et al. (2024) Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. The Lancet. Oncology |
| Choudhury NJ, Lai WV, Makhnin A, et al. (2024) A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Xie M, Vuko M, Rodriguez-Canales J, et al. (2024) Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Molecular Cancer. 23: 115 |
| Tringale KR, Skakodub A, Egger J, et al. (2024) Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. Jco Precision Oncology. 8: e2300470 |
| Spigel DR, Dowlati A, Chen Y, et al. (2024) RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302110 |